<?xml version="1.0" encoding="UTF-8"?>
<p>A number of less frequent symptoms were described during COVID-19, suggesting that SARS-CoV-2 does not remain confined to the respiratory tract. These symptoms, often underestimated, are the feeling of weakness and fatigue, sore throat, stuffy nose, headache, myalgia, asthenia, chills, vomiting, and nausea [
 <xref rid="B70-microorganisms-08-01228" ref-type="bibr">70</xref>]. The central nervous system may be affected with headache, nausea, vomiting, instability, ideomotor slowdown, ataxia, epilepsy; the peripheral nervous system with hypogeusia, hyposmia, and neuralgia and the skeletal muscle system may also be affected [
 <xref rid="B31-microorganisms-08-01228" ref-type="bibr">31</xref>,
 <xref rid="B70-microorganisms-08-01228" ref-type="bibr">70</xref>,
 <xref rid="B77-microorganisms-08-01228" ref-type="bibr">77</xref>,
 <xref rid="B78-microorganisms-08-01228" ref-type="bibr">78</xref>]. Moreover, cases of encephalopathy, encephalitis, necrotizing hemorrhagic encephalopathy, stroke, epileptic seizures, rhabdomyolysis, and Guillain-Barre syndrome have been reported to be associated with SARS-CoV-2 infection [
 <xref rid="B44-microorganisms-08-01228" ref-type="bibr">44</xref>,
 <xref rid="B79-microorganisms-08-01228" ref-type="bibr">79</xref>]. The neuroinvasive propensity of SARS-CoV-2 has, therefore, already been documented in SARS and MERS studies [
 <xref rid="B20-microorganisms-08-01228" ref-type="bibr">20</xref>,
 <xref rid="B29-microorganisms-08-01228" ref-type="bibr">29</xref>]. 
</p>
